Search

Displaying results 1931 - 1940 of 4437 in total
  1. Drug

    Temsirolimus

    go.drugbank.com/drugs/DB06287
    ApprovedInvestigational

    It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

  2. Drug

    Pinacidil

    go.drugbank.com/drugs/DB06762
    Approved

    This drug has been discontinued by the FDA. … Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance.

  3. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    [L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]

  4. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity. … Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production.

  5. Drug

    Norethisterone

    go.drugbank.com/drugs/DB00717
    ApprovedInvestigational

    Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with levonorgestrel and ...

    Mixtures: CLIOVELLE 1MG/0.5MG, ESTRAMON COMP 2MG/1MG
  6. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Some of their side effects are also caused by actions in the CNS.

  7. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells. … [L45698,A258488] Glofitamab was approved by Health Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20

  8. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

  9. Drug

    Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15680
    ApprovedInvestigational

  10. Drug

    Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15681
    ApprovedInvestigational